Mokast (Montelukast)

Montelukast, the active ingredient in Mokast, is a leukotriene receptor antagonist presented as an oral tablet for oral administration. It is used to manage chronic asthma, seasonal allergic rhinitis, and exercise‑induced bronchoconstriction in both adult and pediatric patients, helping to reduce airway inflammation and improve breathing.

GNH USA supplies Mokast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other global markets. The company adheres to stringent quality standards and provides regulatory documentation for importers.

Montelukast acts on leukotriene pathways to treat several respiratory and allergic conditions.

- Asthma: improves control of chronic symptoms and reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: nasopharyngitis or common cold symptoms. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional dry cough.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or angioedema requiring medical attention. - Neuropsychiatric events: mood changes, agitation, or rare suicidal thoughts. - Hepatic dysfunction: abnormal liver enzymes or hepatitis.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

- Assess patient history: review asthma control level and prior leukotriene antagonist response. - Monitor for neuropsychiatric symptoms: observe mood or behavior changes during therapy. - Use cautiously in hepatic impairment: adjust or monitor liver function tests as needed. - Avoid in patients with known hypersensitivity to Montelukast or excipients. - Pregnancy and lactation: evaluate risk‑benefit; limited data available. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital, carbamazepine, rifampin: strong enzyme inducers that may reduce Montelukast plasma levels. - Ritonavir or other potent CYP3A4 inhibitors: may increase exposure, potentially enhancing adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect; monitor INR. - Theophylline: concurrent use may require monitoring of respiratory status. - Antidepressants (e.g., fluoxetine): may modestly increase risk of neuropsychiatric events.